Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 15/20 | 0.80 |
| ▸ | HTR1A | P08908 | 4/20 | 0.80 |
| ▸ | HTR1D | P28221 | 1/20 | 0.80 |
| ▸ | HTR1B | P28222 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510151 | 0.87 | GNRHR (0.75) | GNRHRHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL5505317 | 0.81 | GNRHR (0.84) | GNRHRHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL5505168 | 0.81 | GNRHR (0.82) | GNRHRHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL5514842 | 0.80 | GNRHR (0.81) | GNRHRHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL5510746 | 0.80 | GNRHR (0.83) | GNRHRHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL5510196 | 0.80 | GNRHR (0.83) | GNRHRHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL5509019 | 0.80 | GNRHR (0.85) | GNRHRHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL5503880 | 0.80 | GNRHR (0.82) | GNRHRHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL5506513 | 0.80 | GNRHR (0.83) | GNRHRHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL5515289 | 0.80 | GNRHR (0.82) | GNRHRHTR1AHTR1DHTR1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814866-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006058012-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-06-01 | — | — | WO | claimed |
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-05-25 | — | — | US | claimed |
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | GNRHR, LHCGR, GHRHR | GNRHR 1/4885HTR1A 339/4885HTR1D 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.